{
    "clinical_study": {
        "@rank": "65593", 
        "acronym": "CODI24", 
        "arm_group": {
            "arm_group_label": "DPP-4 inhibition", 
            "arm_group_type": "Placebo Comparator", 
            "description": "A dipeptidyl peptidase-4 (DPP-4) inhibitor (saxagliptin, vildagliptin or sitagliptin) is given before breakfast"
        }, 
        "brief_summary": {
            "textblock": "Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and\n      islet hormones. The study examines this in relation to breakfast, lunch and dinner over an\n      entire 24h study period by the use of three different DPP-4 inhibitors and placebo."
        }, 
        "brief_title": "DPP-4 Inhibition, Incretins and Islet Function", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a single-center study with a cross-over design to examine glycemia, incretin\n      hormones and islet hormones over a 24h study period with standardized breakfast, lunch and\n      dinner after administration of placebo, saxagliptin, vildagliptin or sitagliptin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Caucasian men or women with type 2 diabetes diagnosed according to ICD10 at time of\n             inclusion\n\n               -  Ongoing treatment with life style adjustment including diet and exercise regimen\n                  together with metformin as oral antidiabetic . Metformin therapy should be\n                  stable the last three months\n\n               -  Age 40-75 years\n\n               -  HbA1c 52-80 mmol/mol (inclusive)\n\n               -  BMI: 20-40 kg/m2\n\n               -  Written informed consent has been given\n\n               -  Capability and willingness to participate in the whole study\n\n        Exclusion Criteria:\n\n          -  \u2022 Liver disease (K70-77 in ICD10) or liver enzymes three times above upper reference\n             range\n\n               -  Diabetic nephropathy (GFR < 30 mL/min/1.73 m2 or albuminuria) or other causes of\n                  renal disease\n\n               -  Proliferative diabetic retinopathy\n\n               -  Treatment with any glucose-lowering medication except metformin\n\n               -  Previous myocardial infarction, coronary heart disease or instable angina\n                  pectoris in the last 6 months.\n\n               -  Symptomatic heart failure (NYHA class II-III)\n\n               -  Previous surgery on the gastrointestinal tract\n\n               -  Larger surgical intervention during the last 12 weeks\n\n               -  Female subject who are pregnant or breast feeding\n\n               -  Women of child bearing potential not using a highly effective method of birth\n                  control\n\n               -  Treatment with oral steroids, thiazide diuretics, digoxin or growth hormone\n\n               -  Hypersensitivity to the active substances of to any of the excipients\n\n               -  Participation in another study the last 4 weeks\n\n               -  Smoker\n\n               -  Paracetamol intolerance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089438", 
            "org_study_id": "200A"
        }, 
        "intervention": [
            {
                "arm_group_label": "DPP-4 inhibition", 
                "description": "Saxagliptin (5 mg) is given before breakfast", 
                "intervention_name": "Saxagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Onglyza"
            }, 
            {
                "arm_group_label": "DPP-4 inhibition", 
                "description": "Vildagliptin (50mg) is given before breakfast and dinner", 
                "intervention_name": "Vildagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Galvus"
            }, 
            {
                "arm_group_label": "DPP-4 inhibition", 
                "description": "Sitagliptin (100 mg) is given before breakfast", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Januvia"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vildagliptin", 
                "Sitagliptin", 
                "Saxagliptin", 
                "Incretins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "contact": {
                "email": "Bo.Ahren@med.lu.se", 
                "last_name": "Bo Ahr\u00e9n, MD, PhD", 
                "phone": "+4646220758"
            }, 
            "facility": {
                "address": {
                    "city": "Lund", 
                    "country": "Sweden", 
                    "zip": "22185"
                }, 
                "name": "Clinical Research Department"
            }, 
            "investigator": {
                "last_name": "Bo Ahr\u00e9n, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "Comparison of Three DPP-4 Inhibitors on 24 Hour Blood Glucose, Incretin Hormones and Islet Function in Patients With Type 2 Diabetes", 
        "overall_contact": {
            "email": "Bo.Ahren@med.lu.se", 
            "last_name": "Bo Ahr\u00e9n, MD, PhD", 
            "phone": "+46462220758"
        }, 
        "overall_contact_backup": {
            "email": "Wathik.Alsalim@med.lu.se", 
            "last_name": "Wathik Alsalim, MD", 
            "phone": "+46462220761"
        }, 
        "overall_official": {
            "affiliation": "Lund University", 
            "last_name": "Bo Ahr\u00e9n, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The area under the 180 min curves for plasma glucose after each meal", 
            "measure": "Postprandial glucose", 
            "safety_issue": "No", 
            "time_frame": "180 min"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089438"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lund University", 
            "investigator_full_name": "Bo Ahren", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The area under the 180 min curves for plasma insulin and glucagon after each meal", 
                "measure": "Postprandial insulin and glucagon", 
                "safety_issue": "No", 
                "time_frame": "180 min"
            }, 
            {
                "description": "The area under the 180 min curves for plasma GLP-1 and GIP after each meal", 
                "measure": "Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)", 
                "safety_issue": "No", 
                "time_frame": "180 min"
            }
        ], 
        "source": "Lund University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lund University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}